✦ LIBER ✦

44 Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation

✍ Scribed by M. Griese; B. Ramsey; S. Rodriguez; K. Yen; J.S. Elborn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WS6.3 Measures of nutritional status in

✍ D. Borowitz; B. Ramsey; Q. Dong; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

46 Hyperpolarized Gas MRI of ivacaftor t

✍ T. Altes; M.A. Johnson; G.W. Miller; J.P. Mugler; L. Flors; J. Mata; C.L. Salina 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

43 Patient-reported outcomes in Phase 3

✍ A.L. Quittner; B. Ramsey; Q. Dong; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 67 KB

WS6.4 Long-term safety and efficacy of i

✍ E. McKone; H. Li; K. Yen; J.C. Davies 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Ivacaftor in Subjects With Cystic Fibros

✍ Flume, Patrick A. 📂 Article 📅 2012 🏛 American College of Chest Physicians 🌐 English ⚖ 834 KB

WS6.5 Ivacaftor in subjects 6 to 11 year

✍ J.C. Davies; H. Li; K. Yen; R. Ahrens 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB